The nationwide voluntary recall covers 60 mg extended-release capsules distributed to wholesalers and pharmacies from late October through early November.
BERKELEY HEIGHTS, N.J. — Breckenridge Pharmaceutical Inc. has recalled one lot of propranolol hydrochloride extended-release capsules distributed nationwide after the company identified a risk that the medication could contain metal contamination capable of injuring patients who take it.
The voluntary consumer-level recall, announced Nov. 16, covers Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, packaged in 100-count bottles. The affected product carries lot number PK25110035, National Drug Code 51991-817-01 and an expiration date of May 2029. Breckenridge said the capsules were manufactured by Adare Pharma Solutions and distributed to wholesalers and pharmacies across the United States between Oct. 26 and Nov. 4.
Breckenridge said the recalled lot shared intermediate material with another lot in which metal contamination was identified. The separate lot where the contamination was found was not released to the market. The company did not identify the type, size or amount of metal that may be present in capsules from the recalled lot. The recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
The company said taking capsules from the affected lot could potentially cause cuts to soft tissues in the mouth, esophagus, stomach or intestine. As of its Nov. 16 announcement, Breckenridge said it was not aware of any adverse events that had been assessed as related to the recall. The announcement did not specify how many bottles from the affected lot were distributed or how many may have reached patients.
The recall applies to the identified lot of 60 mg extended-release capsules rather than all propranolol products. The medication label maintained by the National Library of Medicine’s DailyMed database shows that Breckenridge distributes propranolol hydrochloride extended-release capsules in several strengths, including 60 mg, 80 mg, 120 mg and 160 mg. The recalled National Drug Code corresponds to the 60 mg product packaged in bottles of 100 capsules.
Propranolol is a beta-adrenergic blocking drug used to manage high blood pressure and certain other conditions. According to the prescribing information for Breckenridge’s extended-release product, the drug is also indicated for angina, prevention of common migraine headaches and treatment of symptoms associated with hypertrophic subaortic stenosis. The extended-release capsules are designed to provide sustained delivery of propranolol rather than release the full dose at once.
Breckenridge instructed consumers who have medication from the recalled lot to immediately stop taking that affected product and contact a physician or other health care provider for medical advice and replacement instructions. The company said unused capsules from the recalled lot should be returned to the pharmacy where they were obtained. Its prescribing information separately warns that propranolol therapy generally should not be interrupted or stopped without physician guidance because abrupt discontinuation can create cardiovascular risks in some patients.
Wholesalers, pharmacies and other retailers were instructed to inspect their inventories for lot PK25110035, quarantine affected bottles and stop distributing or dispensing them. Businesses that previously distributed the product were told to notify their customers through the retail level. Breckenridge designated Qualanex as its recall service provider for consumer and recall inquiries.
The FDA describes a drug recall as a way to remove defective or potentially harmful medication from the market or alert patients and health professionals to a potential risk. Recalls may be initiated voluntarily by a manufacturer, requested by the FDA or ordered by the agency under circumstances allowed by law. The FDA oversees recall strategies and evaluates whether companies have taken adequate steps to notify customers and address the affected product.
Breckenridge said people who have experienced problems that may be associated with the recalled capsules should contact a health care provider. Adverse reactions and product-quality concerns may also be reported through the FDA’s MedWatch program. No recall-related adverse events had been identified by the company when the recall was announced, and the recall remained focused on the single identified lot.
Author note: Last updated November 18, 2026.